Hello, Welcome to Shine Consultant !
Summit & Event Advisor & Insight Research & Analysis
Guest Information
发布时间: 2018 - 06 - 29
点击次数: 0
Positions: Executive Chairman
Company: Fountain Medical (TIANJIN) Co., Ltd.
个人简介:
Dr. Dan Zhang has more than 10 year of drug development experience. He is the Chief Executive Officer of Fountain Medical Development, a full-service clinical CRO with primary operation in China. Previously, Dr. Zhang was the Head of Clinical Development and Global Safety Assessment at Sigma-Tau Research Inc, a US research arm of Sigma-Tau S.P.A., one of the largest Italy-based pharmaceutical firms with employees of 2300. Dr. Zhang managed the firm’s entire clinical development program in North American market, including oncology, cardiovascular, CNS, and metabolic development projects, in addition to his global role of drug safety handling.Prior to his life at Sigma-Tau, Dr. Dan Zhang was a vice president at the Quintiles Transnational Corp.-the largest contract research organization (CRO) in the world, responsible for the planning and implementation of business development strategies in Greater China Area. He was also a member of Executive Operating Committee of Quintiles Transnational Corp. Dr. Zhang was also the Chairman of the Board, Quintiles Medical Development (Shanghai) Company Ltd., a whollyowned subsidiary of Quintiles Transnational Corp.Before joining Quintiles, Dr. Zhang provided consulting services to many pharmaceutical, medical device and health insurance companies, such as Eli Lilly and Company, Pharmacia & Upjohn, Inc., Medtronic, Inc., and CIGNA Health Care, etc. His consulting services included clinical trial design, health economic studies, pricing and market-entry strategy.Over last ten years, Dr. Zhang established a strong working relationship with government and academic institutions in China. He was a member of the Overseas Expert Committee on New Drug R&D for the Ministry of Science and Technology of China. He was also a visiting professor at the Harbin Medical University of China. In addition, Dr. Zhang was a Ph.D. advisor and consultant for then Shanghai Medical University in the field of Pharmacoeconomic study and clinical trials. He is currently a senior consultant to Chinese Academy of Medical Sciences/Peking Union Medical College. Dr. Zhang was an Executive Director of Sino-American Professional Pharmaceutical Society (SAPA). He was the President (2006~2007), Chinese Biopharmaceutical Association-USA (CBA).Dr. Zhang received his pre-med training from Beijing University and received his M.D. from Peking Union Medical College. He continued his study at the Harvard School of Public Health and received an MPH in health policy and management. Then he continued his training at the Wharton Business School of the University of Pennsylvania, where he obtained his master's degree in healthcare management in 1998 and is working on his Ph.D. dissertation in the field of health economics and finance.Dr. Zhang has published several papers in the fields of medical research and health economics, and is a frequent speaker at various health care-related conferences.
发布时间: 2018 - 07 - 06
点击次数: 0
Positions: Expert
Company: Tongxieyi, New Drug Elite Club / National New Drug Advisory
个人简介:
医学博士,著名免疫学家,国家新药咨询委员,国家自然科学基金专家组成员,吉林大学教授,博士生导师,同写意新药英才俱乐部理事长。 曾任白求恩医科大学副校长,长春市政府副秘书长,国泰国际医药公司常务副总经理等。 现兼任新天域资本、尚珹资本特聘医药专家,四环制药独立董事、国泰国际医药有限公司非执行董事、深圳奥萨医药高级顾问、绿叶制药顾问等。 参加国内多家医药产业园区及医药企业的战略咨询,技术及项目论证等数十次,曾担任多家医药公司的顾问。 多次参加国务院研究发展中心、国家发改委、国家食品药品监督管理局、科技部等组织的咨询及论证会;应邀在国际及全国性会议或论坛上做大会报告或主题演讲(讲座)80余次;并多次组织或主持了全国性及区域性的“生物技术”研讨会或专题报告会。 引荐、协助了20余名留学生回国创业或加盟国内制药公司,其中多家企业已经成为各自领域的行业龙头。 调查了数百家医药及医药相关的公司,遍及全国20多个省份及北美湾区、大费城地区及大波士顿地区等;评价医药及生物技术公司及项目近千项。
发布时间: 2018 - 07 - 06
点击次数: 0
Positions: Founder and CEO
Company: Humanwell Puracap Pharmaceuticals (Wuhan) Co., Ltd
个人简介:
Mr. Dahai Guo is the Founder & CEO of PuraCap Pharmaceutical LLC., Enspire Group LLC. , Chairman & CEO of Humanwell PuraCap Pharmaceutical (Wuhan) Ltd., etc. He is currently managing six affiliate companies in US & China.Under Mr. Guo’s leadership, PuraCap Pharmaceutical & its affiliated companies are one of the leaders in specialty pharma & healthcare industry, who is developing, manufacturing and marketing broad range of Branded Rx, Generic Rx and OTC pharmaceutical products in US & the global markets. Currently, PuraCap & affiliates have over 80 different drugs and over 400 products selling in US, China, Canada and other countries. It has four US FDA inspected manufacturing and packaging facilities in US & China.Through his professional career, Mr. Guo has held senior positions in several multi-billion dollar global companies and also start-up companies in biotech, pharmaceutical and healthcare product industry. He had senior management position in global based public companies like Inverness Medical LLC. (now Aleer), Ansell Healthcare LLC, Roche Group). Mr. Guo has demonstrated strong leadership and broad experience in corporate management, M&A, sales & marketing, product development, global strategic planning and biotechnology research.Before he came to US in mid 1990’s, Mr. Guo conducted molecular biology research at China’s top research institute, Chinese Academy of Sciences. He has introduced various bio-medical products into China market.Mr. Guo has MBA from Cornell University and M.S. of Biology from Rutgers University. He also completed distinguish Six-Sigma Black Belt training, awarded by America Society for Quality. Mr. Guo is current Chairman of BioKatalyst Corp, a non-profit organization whose invited-only members are the top management elites of Chinese Americans crossing healthcare industry.
发布时间: 2018 - 07 - 06
点击次数: 0
Positions: CEO
Company: Genor Biopharma Co. Ltd, Walvax Bio Group
个人简介:
Dr. Zhou, Xinhua (Dr. Joe Zhou) is the CEO of Genor Biopharma, a VP and the R&D head of Walvax Bio Group. He has been selected as a national expert of the TOP 1000 TALENTS program in China since 2010. Dr. Zhou also is a visiting professor teaching Master Degree Program in International Pharmaceutical Engineering Management (IPEM) at Peking University, China. He is an invited vice-chair of Biopharmaceuticals Committee under China Pharmaceuticals Society, the Founder and first Chair of China Protein Drug Quality Alliance (CPDQA), the Founder and first Chair of Biological Drug Product and Process Committee of China ISPE, and the Founder and first Chair of Amgen Aluminums Association (AAA) in China. Previously, Dr. Zhou was Scientific Director at Amgen for bioprocess development and trouble shooting for bioprocess and bio-manufacturing. He has over 20-years industrial experience of process development, multiple project management capacity in cGMP and non-GMP reproducible purification/production of protein/antibody therapeutics from FIH to CPD with depth knowledge of CHO clone selection, cell culture optimization, viral clearance, real time analytical assays, formulation and product specification for drug substances and drug products.